Recently, Brainsway (the company developing the new deep transcranial magnetic stimulation technology) has successfully completed an open label trial on depressed patients. It looks like about 45% of the patients showed a significant response (50% or greater reduction in depressive symptoms) with this treatment. That is a fairly high response rate, and these patients were treatment resistant and had failed at least two prior antidepressants. Comparatively, the response rate in a neuronetics trial for conventional TMS was around 24% (also done with treatment resistant patients). Now Brainsway plans on having a larger double-blind trial to test the efficacy of its device and obtain FDA approval, which could happen in a year or two. Brainsway is also testing its device to improve the cognitive symptoms of schizophrenia, cannabis addiction, post traumatic stress disorder and bipolar disorder.
Friday, February 22, 2008
Deep TMS Clinical Trial
Recently, Brainsway (the company developing the new deep transcranial magnetic stimulation technology) has successfully completed an open label trial on depressed patients. It looks like about 45% of the patients showed a significant response (50% or greater reduction in depressive symptoms) with this treatment. That is a fairly high response rate, and these patients were treatment resistant and had failed at least two prior antidepressants. Comparatively, the response rate in a neuronetics trial for conventional TMS was around 24% (also done with treatment resistant patients). Now Brainsway plans on having a larger double-blind trial to test the efficacy of its device and obtain FDA approval, which could happen in a year or two. Brainsway is also testing its device to improve the cognitive symptoms of schizophrenia, cannabis addiction, post traumatic stress disorder and bipolar disorder.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment